Beta blockers as anti-arrhythmic agents

Heart Failure Reviews

Volumn 9, Issue 2, 2004, Pages 139-147

  Anh, Daejoon ^a   Marine, Joseph E ^a,b  

^a Henry Ford Heart/Vascular Institute   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic beta antagonists; Anti arrhythmia agents; Cardiac; Death; Sudden; Tachycardia; Ventricular; Ventricular fibrillation

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISOPROLOL; BRETYLIUM; BUCINDOLOL; CARVEDILOL; DIHYDROPYRIDINE; DOBUTAMINE; LABETALOL; LIDOCAINE; METOPROLOL; METOPROLOL TARTRATE; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; PINDOLOL; PLACEBO; PROCAINAMIDE; PROPRANOLOL; TIMOLOL; XAMOTEROL HYDROGEN FUMARATE;

ADRENERGIC STIMULATION; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG RELEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; REVIEW; SUDDEN DEATH; SURVIVAL; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 8444230436     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HREV.0000046369.90417.db     Document Type: Review

References (68)

1. http://www.cdc.gov/mmwr/preview/mmwrhtml/00054249.htm
2. Stevenson WG, Stevenson LW, Middlekauff HR, Saxon LA. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 1993;88:2953-2961.
3. http://www.acc04online.org/ondemand/trials1/sessions.asp?link=W (online link to SCD-HeFT presentation)
4. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991 324(12):781-788.
5. Krishnan SC, Schuger CD, Goldstein S. Sudden death in heart failure: Underlying electrophysiological mechanisms. Heart Failure Reviews 2002;7(3):255-260.
6. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998 98(21):2334-2351.
7. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, Kass D, Feldman AM, Marban E. Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation 1994 ;90(5):2534-2539.
8. Bueckelmann DJ, Näbauer M, Erdmann E. Intracellular calciumm handling in ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
9. Maltsev VA, Sabbah HN, Higgins R, et al. Novel, ultra-slow inactivating sodium current in human ventricular cardiomyocytes. Circulation 1998;98:2545-2552.
10. John RM, Taggart PI, Sutton PM, Costa DC, Ell PJ, Swanton H. Endocardial monophasic action potential recordings for the detection of myocardial ischemia in man: A study using atrial pacing stress and myocardial perfusion scintigraphy. American Heart Journal 1991 122(6):1599-1609.
11. Qin D, Zhang ZH, Caref EB, Boutjdir M, Jain P, El-Sherif N. Cellular and Ionic Basis of Arrhythmias in Postinfarction Remodeled Ventricular Myocardium. Circ Res 1996;79:461-473.
12. Verrier RL, Antzelevitch C. Autonomic aspects of arrhythmogenesis: The enduring and the new. Current Opinion in Cardiology 2004 19(1):2-11.
13. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, Schwaiger M. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: An analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 1999;81:262-2670.
14. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 1990;82(4):1095-1105.
15. Barber MJ, Mueller TM, Henry DP, Felten SY, Zipes DP. Transmural myocardial infarction in the dog produces sympathectomy in noninfarcted myocardium. Circulation 1983;67(4):787-796.
16. Dae MW, Herre JM, O'Connell JW, Botvinick EH, Newman D, Munoz L. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 1991 17(6):1416-1423.
17. Herre JM, Wetstein L, Lin YL, Mills AS, Dae M, Thames MD. Effect of transmural versus nontransmural myocardial infarction on inducibility of ventricular arrhythmias during sympathetic stimulation in dogs. J Am Coll Cardiol 1988;11(2):414-421.
18. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovascular Research 2001 50(2):409-416.
19. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, Chen PS, Chen LS. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000;101(16):1960-1969.
20. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82(5):1724-1729.
21. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
22. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998;82:91-191.
23. Lowe MD, Rowland E, Brown MJ, Grace AA. Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium. Heart 2001;86(1):45-51.
24. Swann ME, Nakagawa H, Vanoli E, Lazzara R, Schwartz PJ, Adamson PB. Heterogeneous regional endocardial repolarization is associated with increased risk for ischemia-dependent ventricular fibrillation after myocardial infarction. J Cardiovasc Electrophysiol 2003 14(8):873-879.
25. John RM, Taggart PI, Sutton PM, Ell PJ, Swanton H. Direct effect of dobutamine on action potential duration in ischemic compared with normal areas in the human ventricle. J Am Coll Cardiol 1992 20(4):896-903.
26. Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion. Am J Cardiol 1975;36:45-49.
27. O'connor CM, Gattis WA, Uretsky BF, Adams KA, McNulty S, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM. Continuous intravenous dobufamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). American Heart Journal 1999;138:78-86.
28. Chatterjee K, De Marco T. Role of nonglycosidic inotropic agents: Indications, ethics, and limitations. The Medical Clinics of North America 2003;87:391-418.
29. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New England Journal of Medicine 1991 ;325(21):1468-1475.
30. Sabbah HN, Goldberg AD, Schoels W, Kono T, Webb C, Brachmann J, Goldstein S. Spontaneous and inducible ventricular arrhythmias in a canine model of chronic heart failure: Relation to haemodynamics and sympathoadrenergic activation. European Heart Journal 1992 ;13:1562-1572.
31. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. The New England Journal of Medicine 1991;325:618-624.
32. Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196-1202.
33. Billman GE, Castillo LC, Hensley J, Hohl CM, Altschuld RA. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: In vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96(6):1914-1922.
34. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: Acute ischemia versus myocardial substrate. Circulation 1997;96(9):3215-3223.
35. Cleophas TJ, Marum R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol 2001;87:487-490.
36. Ryden L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, Reyes C, Smedgard P, Svedberg K, Vedin A, Waagstein F, Waldenstrom A, Wilhelmsson C, Wedel H, Yamamoto M. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983;308(11):614-618.
37. Norris RM, Barnaby PF, Brown MA, Geary GG, Clarke ED, Logan RL, Sharpe DN. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984;2(8408 ):883-886.
38. Goldstein S. for the BHAT Research Group. Propanolol therapy in patients with acute myocardial infarction: The beta-blocker heart attack trial. Circulation 1983; 67(Supp I):53-57.
39. Huikuri HV, Cox M, Interian A, Kessler KM, Glicksman F, Castellanos A, Myerburg RJ. Efficacy of intravenous propanolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristics in coronary artery disease. Am J Cardiol 1989;64:1305-1309.
40. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: Sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000;102(7):742-747.
41. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101(6):616-623.
42. Piccirillo G, Luparini RL, Celli V, Moise A, Lionetti M, Marigliano V, Cacciafesta M. Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. Am J Cardiol 2000;86(12):1392-1395.
43. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36(5):1612-1618.
44. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: Differential effects on sympathetic activity. Circulation 2001 104(18):2194-2199.
45. Cice G, Tagliamonte E, Ferrara L, Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebo-controlled study. European Heart Journal 2000;21(15):1259-1264.
46. Piccirillo G, Quaglione R, Nocco M, Naso C, Moise A, Lionetti M, Di Carlo S, Marigliano V. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002 ;90(10): 1113-1117.
47. Klingenheben T, Gronefeld G, Li YG, Hohnloser SH. Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. J Am Coll Cardiol 2001;38(7):2013-2019.
48. Teerlink JR, Massie MM. The role of beta blockers in preventing sudden death in heart failure. Journal of Cardiac Failure 2000;6(2) Suppl.1:25-33.
49. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet 1997;349:662-663.
50. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80(6):1675-1680.
51. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients with implantable cardioverter defibrillators: The importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002;39(8):1323-1328.
52. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993 342(8885):1441-1446.
53. Teerlink JR, Massie BM. Beta-adrenergic blocker mortality trials in congestive heart failure Am J Cardiol 1999;84(9A):94R-102R.
54. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90(4):1765-1773.
55. The Cardiac Insufficiency, Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353(9146):9-13.
56. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-2007.
57. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler AM, Gilbert EM, Shusterman NE. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New England Journal of Medicine 1996 334(21):1349-1355.
58. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997 349(9049):375-380.
59. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. The Lancet 2001;357(9266):1385-1390.
60. McMurray JJ, Dargie HJ, Sendon JLL, et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: Evidence from the CAPRICORN study. Circulation 2001;104:II-700.
61. Packer M, Coats AJ, Fowler AM, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine 2001; 344(22):1651-1658.
62. Packer M, Fowler AM, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106(17):2194-2199.
63. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine 2001 May 31 344(22):1659-1667.
64. Bristow M. Antiadrenergic therapy of chronic heart failure surprises and new opportunities. Circulation 2003;107:1100-1102.
65. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, Bishopric NH. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105(20):2429-2434.
66. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003 ;362(9377):7-13.
67. Bristow MR, Feldman AM, Adams KF, Jr, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: Are there lessons to be learned from the COMET trial? J Card Fail 2003;9(6):444-453.
68. Hjalmarson A, Waagstein F. COMET: A proposed mechanism of action to explain the results and concerns about dose. Lancet 2003 362(9389):1077; author reply 1077-1078.